|
Radium-223 re-treatment in an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases: 2-year follow-up. |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Oncogenex; Pfizer; Sanofi |
Research Funding - Bayer (Inst); Endocyte (Inst); Innocrin Pharma (Inst); Johnson & Johnson (Inst); Merck; Sanofi (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Bellicum Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Progenics; Sanofi; Tokai Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen-Cilag; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; Pfizer |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche; Sanofi |
Travel, Accommodations, Expenses - Bayer; Bayer; Janssen Oncology; Pfizer; Sanofi |
|
Camilla Thellenberg Karlsson |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Janssen; MSD; Roche; Sanofi |
|
|
Consulting or Advisory Role - Bayer; IPSEN; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
Employment - Bayer; Merck |
Stock and Other Ownership Interests - Amgen; Bayer; Merck |
|
|
|
Stock and Other Ownership Interests - Bayer |
|
|
No Relationships to Disclose |